Brief: Argenx Discontinues Phase 3 Unity Study Of Efgartigimod SC In Sjögren's Disease
08/10/2026 07:59
BRIEF-Argenx Discontinues Phase 3 Unity Study Of Efgartigimod SC In Sjögren's Disease Oct 8 (Reuters) - argenx SE ARGX.BR:
PROVIDES UPDATE ON PHASE 3 UNITY STUDY OF EFGARTIGIMOD SC IN SJÖGREN'S DISEASE
PROVIDES UPDATE ON PHASE 3 UNITY STUDY OF EFGARTIGIMOD SC IN SJÖGREN'S DISEASE
DISCONTINUATION BASED ON IDMC RECOMMENDATION TO STOP STUDY FOR FUTILITY
UNITY STUDY UNABLE TO MEET PRIMARY ENDPOINT
NO NEW SAFETY SIGNALS IDENTIFIED IN UNITY STUDY
IDMC CONCLUDED THAT THE UNITY STUDY IS UNABLE TO MEET ITS PRIMARY ENDPOINT.
Source text: ID:nGNXbHt2wL
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))